Girona

• Clinical trial to compare efficacy and safety of standard chemotherapy versus letrozole plus abemaciclib, chosen randomly, as neoadjuvant th … Ended recruitment
  2024-514395-40-00 4 2020-08-25 High/intermediate risk hormone receptor (HR) positive/human epidermal
• A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed … Ended recruitment
  2022-502746-27-00 5 2020-08-21 Endometrial Cancer
• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended recruitment
  2023-505830-89-00 6 2020-08-05 metastatic castrate resistant prostate cancer (mCRPC)
• A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with F … Ended recruitment
  2024-515379-36-00 9 2020-08-04 Metastatic pancreatic ductal adenocarcinoma
• CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi … Ended recruitment
  2023-509089-39-00 5 2020-07-01 Non-Muscle Invasive Bladder Cancer
• Extension of a clinical trial to assess the safety of a study drug called "CORT125134" in the treatment of Cushing Syndrome Ended recruitment
  2024-514079-17-00 10 2020-05-28 Endogenous Cushing Syndrome
• Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera … Ended recruitment
  2022-501973-37-00 5 2020-01-30 Endometrial cancer
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended recruitment
  2024-510776-20-00 5 2019-10-25 Female or male patients with histologically confirmed HR-positive, HER
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• Trial of dostarlimab (TSR-042) for patients with high-risk locally advanced cervical cancer after chemo-radiation Ended recruitment
  2023-510268-11-00 4 2019-06-11 Cervical cancer
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended recruitment
  2024-510985-17-00 4 2019-03-14 First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
• Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended recruitment
  2023-507564-39-00 1 2019-03-11 Patients with Advanced Solid Tumors
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year … Ended recruitment
  2024-516905-22-00 5 2018-10-22 Multiple myeloma
• A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject … Ended recruitment
  2023-506112-40-00 5 2018-09-26 R/R Multiple Myeloma
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi … Ended recruitment
  2024-510967-41-00 5 2018-09-21 Metastatic colorectal cancer
• LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended recruitment
  2023-507657-15-00 5 2018-09-13 Ulcerative Colitis
• Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended recruitment
  2024-513206-65-00 5 2018-08-10 resected squamous cell carcinoma of head and neck

Showing 193–216 of 287 trials